Suchergebnisse - "Shiotsu, Shinsuke"

PubPharm (7)

1

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50

enthalten in: Frontiers in immunology | 2024

von Takei, S. | Kawachi, H. | Yamada, T. | +20

2

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression : Focus on the Role of Performance Status

enthalten in: Targeted oncology | 2023

von Morimoto, K. | Yamada, T. | Kawachi, H. | +19

3

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer

enthalten in: JAMA network open | 2023

von Kawachi, H. | Yamada, T. | Tamiya, M. | +19

CommentIn: JAMA Netw Open. 2023 Jul 3;6(7):e2322922. - PMID 37432691

4

Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations : a multicenter retrospective study

enthalten in: Journal of cancer research and clinical oncology | 2023

von Hata, T. | Sakaguchi, C. | Hirano, K. | +11

5

Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy

enthalten in: Drugs & aging | 2023

von Morimoto, K. | Yamada, T. | Takeda, T. | +14

6

Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation : A multicenter retrospective study

enthalten in: Thoracic cancer | 2023

von Hata, T. | Sakaguchi, C. | Hirano, K. | +11

7

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib

enthalten in: Cancer science | 2023

von Yoshimura, A. | Yamada, T. | Serizawa, M. | +25

1
[1]